FindTrial
Sign In

Efficacy and Safety of Xihuang Capsule on Radiotherapy-induced Oral Mucositis in Patients with Head and Neck Cancer

Clinical Study of Xihuang Capsule on Radiation-induced Oral Mucositis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018036
Enrollment
Unknown
Registered
2018-08-27
Start date
2018-08-27
Completion date
Unknown
Last updated
2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiation-induced oral mucositis

Interventions

Treatment group:Xihuang Capsule
Control group:Recombinant Human Epidermal Growth Factor Derivative For External Use, Liquid (rhEGF)

Sponsors

Huangshi Central Hospital of EDong Healthcare
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Patients with previously untreated, non-distant metastatic, newly pathologically confirmed head and neck cancer (stage III-IVB according to the American Joint Committee on Cancer, 7th edition (2010)) and were prepared for chemoradiotherapy were eligibled. Patients had to be 18-59 years old, expected survival time of =6 months, Eastern Cooperative Oncology Group (ECOG) score of =2, no history of oral and salivary gland disease and adequate bone marrow, liver, and renal function.

Exclusion criteria

Exclusion criteria: pregnancy or lactation, poor oral hygiene and active oral diseases, taking other drugs for treatment of oral mucositis, or any severe coexisting diseases.

Design outcomes

Secondary

MeasureTime frame
The Time Onset of Oral Mucositis;Cumulative Radiation Dose;—

Primary

MeasureTime frame
Radiation-induced Oral Mucositis Score;Oral Pain Score;—

Countries

China

Contacts

Public ContactFei Xinxiong
fxx6225234@sina.com+86 18972772165

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026